As Zimmer Biomet prepares to enter a surging robotics market, CEO Bryan Hanson said the company wants to make sure the company does it right.
Edwards might be primarily known for its TAVR systems, but the company has been making some interesting forays into the artificial intelligence realm.
The NAVIGATE study evaluating electromagnetic navigation bronchoscopy (ENB) procedures using the superDimension navigation system to aid in lung cancer diagnosis, staging, and treatment.
The Tempe, AZ-based company has raised $10M in a series A to help further commercialize the Gamma Tile, surgically targeted radiation therapy for patients with brain tumors.
Stryker reported strong performance in the fourth quarter of 2018 with a record number of robots installed and a healthy order book going into 2019.
The Massachusetts Medical Device Development Center is hosting its annual startup competition to identify disruptive medtech and biotech companies. Up to 20 finalists will become eligible to win a share the $200,000 purse of sponsor-provided, in-kind services.
The Marlborough, MA-based company’s device treats benign prostatic hyperplasia, and was obtained when it acquired NxThera for $406 million.
How surgeons are using virtual reality technology to simulate digital operating rooms and complex medical procedures to improve patient outcomes.
The Warsaw, IN-based company has received clearance for the ROSA Knee System to be used in robotically-assisted total knee replacement procedures.
In a recent analyst report, Canaccord Genuity's Jason Mills highlighted 16 potentially disruptive medtech companies in the private sector.
Abbott CEO Miles White says the company is adding 300,000 new Freestyle Libre patients per quarter and growing. More than 1.3 million diabetes patients are currently using the device for continuous glucose monitoring.
MD+DI takes a look at five deals that transformed companies for the better and five deals that resulted in controversy for the parties involved.
Johnson & Johnson did improve performance in its medical device business last year, but CEO Alex Gorsky said the company has more work ahead to return to above-market growth in 2020.
The late-stage biopharmaceutical company is leveraging capital investment to advance its soft mist inhaled insulin product toward phase III trials and build a leadership team.